Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MYC | P01106 | 2/20 | 0.36 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.36 |
| ▸ | USP14 | P54578 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14022008 | 0.78 | KDM4E (0.58) | KDM4EALDH1A1L3MBTL1MAPTKMT2A | |
| SCHEMBL2273392 | 0.75 | KDM4E (0.55) | KDM4EALDH1A1L3MBTL1MAPTKMT2A | |
| SCHEMBL1838882 | 0.75 | KDM4E (0.59) | KDM4EALDH1A1L3MBTL1MAPTKMT2A | |
| SCHEMBL10673112 | 0.74 | KMT2A (0.41) | KDM4EALDH1A1L3MBTL1MAPTKMT2A | |
| SCHEMBL12349892 | 0.73 | ALDH1A1 (0.38) | KDM4EALDH1A1L3MBTL1MAPTKMT2A | |
| SCHEMBL23565507 | 0.72 | TDP1 (0.48) | KDM4EALDH1A1L3MBTL1MAPTKMT2A | |
| SCHEMBL2269126 | 0.72 | ALDH1A1 (0.51) | KDM4EALDH1A1L3MBTL1MAPTKMT2A | |
| SCHEMBL13268136 | 0.72 | KDM4E (0.51) | KDM4EALDH1A1L3MBTL1MAPTKMT2A | |
| SCHEMBL13248484 | 0.72 | ALDH1A1 (0.51) | KDM4EALDH1A1L3MBTL1MAPTKMT2A | |
| SCHEMBL17477885 | 0.71 | KDM4E (0.50) | KDM4EALDH1A1L3MBTL1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291645-B2 | Phenylalanine derivatives as alpha 4 integrin inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7015216-B2 | Heteroaryl-β-alanine derivatives as alpha 4 integrin inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2006-03-21 | — | — | US | disclosed |
| US-20040127486-A1 | Phenylalanine derivatives as alpha 4 integrin inhibitors | ELAN PHARMACEUTICALS, INC. | 2004-07-01 | — | — | US | disclosed |
| US-6689781-B2 | TREATING AN INFLAMMATORY CONDITION IN A MAMMALIAN PATIENT WHICH CONDITION IS MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. | 2004-02-10 | — | — | US | disclosed |
| US-20020086882-A1 | Heteroaryl-beta-alanine derivatives as alpha 4 integrin inhibitors | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2002-07-04 | — | — | US | disclosed |
| US-20020055509-A1 | Phenylalanine derivatives as alpha 4 integrin inhibitors | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2002-05-09 | — | — | US | disclosed |
| US-20020028812-A1 | Phenylalanine derivatives | CELLTECH CHIROSCIENCE LIMITED (GB) | 2002-03-07 | — | — | US | disclosed |
| US-6348463-B1 | Phenylalanine derivatives | CELLTECH THERAPEUTICS LIMITED (GB) | 2002-02-19 | — | — | US | disclosed |
| WO-2002008206-A1 | 3-AMINO-2-(4-AMINOCARBONYLOXY)PHENYL-PROPIONIC ACID DERIVATIVES AS ALPHA-4- INTEGRIN INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055509-A1 | Phenylalanine derivatives as alpha 4 integrin inhibitors | ITGB4, ITGA4, ITGB3 | KDM4E 469/4885ALDH1A1 1200/4885L3MBTL1 1052/4885 |
| US-20020086882-A1 | Heteroaryl-beta-alanine derivatives as alpha 4 integrin inhibitors | ITGAL, ITGB4, ITGA4 | KDM4E 2953/4885ALDH1A1 593/4885L3MBTL1 1309/4885 |
| US-20020028812-A1 | Phenylalanine derivatives | PAH, FPR1, VCAM1 | KDM4E 1423/4885ALDH1A1 330/4885L3MBTL1 386/4885 |
| US-20040127486-A1 | Phenylalanine derivatives as alpha 4 integrin inhibitors | ITGB4, ITGA4, ITGB3 | KDM4E 469/4885ALDH1A1 1200/4885L3MBTL1 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.